Easterly Investment Partners’s Biogen BIIB Stock Holding History

Easterly Investment Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$534K	–	188
2022 Q3	$534K	Buy	+2,000	New	+$425K	0.05%	153

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Easterly Investment Partners's BIIB Position: Q2 2024 in Review

Easterly Investment Partners sold out of Biogen (BIIB) in Q2 2024, closing a stake of 41,942 shares — an estimated $9.04M sold.

Easterly Investment Partners first reported a position in BIIB in Q3 2021 and held it in 11 quarters. The position peaked at $9.04M in Q1 2024. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Easterly Investment Partners reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Easterly Investment Partners sold 41,942 Biogen shares in Q2 2024, an estimated $9.04M.
Easterly Investment Partners first reported a position in Biogen in Q3 2021 and held it in 11 quarters.
Easterly Investment Partners's Biogen position peaked at $9.04M in Q1 2024.
944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Easterly Investment Partners's 13F filing for Q2 2024, filed 25 Jul 2024.